ZURICH : The Swiss Agency for Therapeutic Products, Swissmedic on Friday approved the use of the Pfizer vaccine for children aged 5-11.
“Swissmedic has carefully examined all the data submitted with the application for an indication extension for the COVID-19 vaccine from Pfizer/BioNTech (Comirnaty®). The clinical trial results show that the vaccine is safe and effective in this age group … it will thus be possible for children aged 5 years and older to be vaccinated against the new coronavirus (SARS-CoV-2) in accordance with the federal government’s updated vaccination recommendations,” Swissmedic said in a statement on its website.
The agency said the study involving over 1,500 participants showed that the vaccine provides almost complete protection for children aged 5-11 against COVID-19. The agency added that the side effects included pain at the injection site or tiredness, sometimes headaches, aches in limbs and fever.
Read More
- H-1B visa extension fee unlikely to outweigh cost of losing skilled talent
- No decision yet on US talks, Iran says as Hormuz tensions rise
- Colombia quake toll hits 287 as rescuers race to find survivors
- 7.4-magnitude earthquake jolts Indonesia, followed by two in Flores Sea
- Dubai to roll out ‘Rent Now, Pay Later’ plan with 12-month, zero-interest payments
According to the latest data, 66 percent of Swiss nationals have been fully vaccinated against COVID-19. (ANI/Sputnik)
